Drug intelligence / Profile preview

rabbit anti-thymocyte globulin + cyclosporine or tacrolimus

Development stage
Unknown
Lead developer
Sanofi
Modality
Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous, Oral
01

Overview

Rabbit anti-thymocyte globulin is a polyclonal antibody preparation derived from rabbits immunized with human thymocytes. It is used as an immunosuppressive agent to prevent and treat acute rejection in organ transplantation, particularly kidney and liver transplants. The mechanism of action involves binding to multiple T-cell specific antigens, leading to T-cell depletion via complement-mediated cytotoxicity or apoptosis, and induction of regulatory T-cells[1][3][4][5][6]. Cyclosporine and tacrolimus are calcineurin inhibitors that suppress the immune response by inhibiting interleukin 2 production in activated T-helper cells, thereby reducing proliferation of cytotoxic T-cells responsible for graft rejection[8]. This combination regimen is commonly used for prophylaxis against acute rejection in solid organ transplantation.

Other names
antithymocyte immunoglobulin (rabbit)anti-thymocyte globulin (rabbit)rabbit anti-thymocyte globulinATG-rabbitcyclosporinetacrolimus
02

Targets

CN (Calcineurin)FKBP1ACD3 (T-cell surface glycoprotein CD3)PPIA (Peptidyl-prolyl cis-trans isomerase A)

Beyond the preview

Go deeper on rabbit anti-thymocyte globulin + cyclosporine or tacrolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rabbit anti-thymocyte globulin + cyclosporine or tacrolimus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call